SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)
$IMGN
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/1/2023 | $25.00 → $31.00 | Buy → Neutral | Guggenheim |
11/20/2023 | $17.00 | Neutral | Goldman |
11/9/2023 | $25.00 | Buy | Deutsche Bank |
10/6/2023 | $16.00 | Perform | Oppenheimer |
5/3/2023 | $6.00 → $16.00 | Neutral → Overweight | Piper Sandler |
11/21/2022 | $10.00 | Buy | Truist |
9/9/2022 | $8.00 | Overweight | Barclays |
3/21/2022 | $9.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
4 - ImmunoGen, Inc. (0000855654) (Issuer)
4 - ImmunoGen, Inc. (0000855654) (Issuer)
4 - ImmunoGen, Inc. (0000855654) (Issuer)